AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32459005
Drug: Zoledronate (ZOL)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate (ZOL) administered 6 months after last denosumab injection (6M group, n = 20)
Trial: 32459005
Drug: Zoledronate (ZOL)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate (ZOL) administered 9 months after last denosumab injection (9M group, n = 20)
Trial: 32459005
Drug: Zoledronate (ZOL)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate (ZOL) administered when bone turnover had increased (OBS group, n = 21)
Trial: 33649927
Drug: Vaginal wall
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal wall injection
Trial: 35981118
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (MBI), 8-week personalized yoga therapy.
Trial: 33704052
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating film of varenicline salicylate (test drug)
Trial: 33704052
Drug: Film‐coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film‐coated tablets of varenicline tartrate (reference drug)
Trial: 32717999
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg mango leaf extract (Zynamite®)
Trial: 35389303
Drug: Calendula officinalis
RxNorm normalized name: Calendula officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calendula officinalis L.
Trial: 32967390
Drug: Intradiscal ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal ozone therapy (Group 1)
Trial: 32967390
Drug: Intradiscal ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal ozone therapy with periforaminal steroid injection (Group 2)
Trial: 36172861
Drug: Quarterly antibiotic-prescribing
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarterly antibiotic-prescribing feedback reports
Trial: 33871558
Drug: LEU-PRO (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEU-PRO (3 g leucine, 10 g protein; n=38)
Trial: 33871558
Drug: LEU-PRO+n-3 (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEU-PRO+n-3 (0.8 g EPA, 1.1 g DHA; n=38)
Trial: 34871570
Drug: Tafenoquine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 300 mg
Trial: 35596578
Drug: THC (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (8 mg)
Trial: 33048249
Drug: Deep learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning algorithm predicting ODI after treatment
Trial: 33048249
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of actual patient values after 6 months with predictions for alternative therapy
Trial: 32332590
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with music (CBT-music)
Trial: 33400421
Drug: Nutrafol® Women’s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrafol® Women’s Balance Capsules
Trial: 35822412
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole magnesium (test)
Trial: 35822412
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole magnesium (reference)
Trial: 35822412
Drug: Esomeprazole administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole administered while fed
Trial: 32853704
Drug: Treatment intensity
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensity (25 hours per week)
Trial: 32853704
Drug: Treatment intensity
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensity (15 hours per week)
Trial: 33001255
Drug: Daily probiotic
RxNorm normalized name: CVS Daily Probiotic Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily probiotic group (Lactobacillus paracasei SD1 once daily)
Trial: 33074709
Drug: Tauroursodeoxycholic acid
RxNorm normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholic acid (TUDCA) 1,500 mg
Trial: 36389724
Drug: Anti-PD-1 adjuvant
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 adjuvant therapy (intravenous injection of 200 mg, repeated every 3 weeks for a total of 4 or 8 cycles)
Trial: 36389724
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-PD-1 therapy)
Trial: 36389724
Drug: Anti-PD-1 adjuvant
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 adjuvant therapy
Trial: 35136033
Drug: First-generation antipsychotics
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotics (haloperidol or perphenazine)
Trial: 35136033
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PRS and clinical data
Trial: 33166719
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off
Trial: 35707974
Drug: 500‐mL intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mL intravenous fluid bolus
Trial: 33657849
Drug: Combined Intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Intravenous Thrombolysis (IVT) and Mechanical Thrombectomy (MT)
Trial: 32045493
Drug: TAK-079 (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 (0.06 mg/kg i.v.)
Trial: 32045493
Drug: TAK-079 (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 (0.6 mg/kg s.c.)
Trial: 32045493
Drug: TAK-079 (≥0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 (≥0.3 mg/kg s.c.)
Trial: 36076211
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (1000 mg dose at enrolment)
Trial: 36076211
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate (195 mg elemental iron daily, thrice daily from enrolment till 6 weeks postpartum)
Trial: 32499262
Drug: NAVIGATE intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAVIGATE intervention (individualised medication management, individual resiliency training, supported employment and education, family education)
Trial: 35879178
Drug: BoNTA (5U/0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNTA (5U/0.05 mL)
Trial: 32253271
Drug: High-dose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IV iron
Trial: 32253271
Drug: Low-dose IV
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IV iron
Trial: 34158778
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (2 gr) over 30 minutes
Trial: 32517660
Drug: Natural rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural rectal progesterone (800 mg daily)
Trial: 34241801
Drug: Buxue Yimu
RxNorm normalized name: Buxus Chinensis Oil
DrugBank: Jojoba oil (DB14252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buxue Yimu Pills (BYP, 24 g/d)
Trial: 34241801
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BYP and FS (BYP, 24 g/d plus FS Tablets, 0.9 g/d)
Trial: 35235002
Drug: Fingolimod-discontinuation group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod-discontinuation group
Trial: 32319006
Drug: BZD tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BZD tapering
Trial: 32319006
Drug: Pharmaceutical GHB
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical GHB tapering
Trial: 35817643
Drug: 3 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sessions of radial extracorporeal shockwave therapy (rESWT)
Trial: 35817643
Drug: minimal-dose rESWT
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minimal-dose rESWT
Trial: 33382448
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (3×1000 mg/day, 0.5 mEq/kg)
Trial: 33382448
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (2×1000 mg/day)
Trial: 32162274
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate 100 mg BID
Trial: 34301751
Drug: Ramucirumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (10 mg/kg) plus Erlotinib (150 mg/day)
Trial: 39622410
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Erlotinib (150 mg/day)
Trial: 36201089
Drug: Biweekly TAS-102
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly TAS-102 (35 mg/m2 twice daily on days 1-5 and 15-19 in a 4-week cycle) and bevacizumab (5 mg/kg every 2 weeks)
Trial: 33856729
Drug: Flaxseed supplementation
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed supplementation (30 g/day ground flaxseed powder)
Trial: 32576131
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion 0.25 μg/kg/min
Trial: 32576131
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion 1ug/kg/min with propofol 50-150 ug/kg/min
Trial: 36056577
Drug: PSA <
RxNorm normalized name: Prostate-Specific Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA < 1 ng/mL
Trial: 36056577
Drug: PSA 1.0-1.99
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA 1.0-1.99 ng/mL
Trial: 36056577
Drug: PSA 2-2.99
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA 2-2.99 ng/mL
Trial: 33540206
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy – Cognitive Therapy version (CPT-C)
Trial: 35555185
Drug: Acipimox (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (50 mg/kg/day)
Trial: 32757413
Drug: Nabilone (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (median dose = 0.75 mg)
Trial: 35487685
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of 5.1 pg/mL in sNfL levels between baseline and 6 years
Trial: 34932107
Drug: Multiorgan focused
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiorgan focused clinical ultrasonography (FCU) performed by an internal medicine physician in addition to standard clinical evaluation
Trial: 33144354
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose treatment
Trial: 2011528253
Drug: Monochromatic infrared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochromatic infrared energy (MIRE) therapy, daily for a total of 12 treatments
Trial: 32309857
Drug: HP rs2000999
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP rs2000999 G allele
Trial: 33527576
Drug: L-menthol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol (160 mg)
Trial: 32779141
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS reminders with medication treatment
Trial: 32779141
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 4-week medication treatment without reminders
Trial: 32011497
Drug: pregabalin +
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin + electro-acupuncture (EA) treatment
Trial: 32011497
Drug: pregabalin +
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin + Chuna manual therapy (CMT) treatment
Trial: 32011497
Drug: pregabalin administration
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin administration
Trial: 32199584
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid treatment within 3 hours after the onset of acute bleeding
Trial: 32533015
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene products containing stannous ions (TG)
Trial: 33385439
Drug: Ketamine (subanesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (subanesthetic dose)
Trial: 35102968
Drug: Probiotic curd
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic curd (Amul's Probiotic Dahi) containing Lactobacillus acidophilus (La5) and Bifidobacterium lactis (Bb12), 100 g two times a day for 21 days
Trial: 35728909
Drug: Telepharmacy care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepharmacy care group (customised mobile application and monthly telecommunications)
Trial: 32713561
Drug: Intradialytic exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic exercise (twice a week for 8 weeks)
Trial: 33059105
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1000 mg in 200 mL normal saline)
Trial: 33059105
Drug: Epinephrine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (1 mg in 200 mL normal saline)
Trial: 35588372
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of renal replacement therapy (RRT)
Trial: 35190080
Drug: MyTeachingPartner (MTP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyTeachingPartner (MTP) coaching; specific dosage not mentioned; duration not specified.
Trial: 33416918
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation therapy with vitamin-K antagonists
Trial: 33416918
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation therapy with direct oral anticoagulants
Trial: 34842775
Drug: Low-Dose External
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose External Beam Radiotherapy (LD-EBRT) 6 × 0.5 Gy
Trial: 33328187
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2.5 mg intravitreal bevacizumab and subconjunctival Mitomycin C (group A)
Trial: 34004448
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (9 g/day for 2 weeks)
Trial: 33148277
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin administration
Trial: 34036915
Drug: 50 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg/day levothyroxine for 2 months
Trial: 33397249
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg daily for 8 weeks)
Trial: 33397249
Drug: Nano-curcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (80 mg daily for 8 weeks)
Trial: 33397249
Drug: Placebo (capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsules like curcumin)
Trial: 34278433
Drug: On-demand oral
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand oral TDF/emtricitabine for PrEP
Trial: 34669884
Drug: Modified tissue-selecting
RxNorm normalized name: Tissue Goo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified tissue-selecting therapy stapler combined with complete anal canal preservation surgery
Trial: 32349353
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of potato protein isolate (PP) twice daily (1.6 g/kg/d total protein)
Trial: 32349353
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (CON) (0.8 g/kg/d total protein)
Trial: 35304396
Drug: CRT (50.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT (50.4 Gy with capecitabine) followed by consolidation chemotherapy (six cycles of CapeOx)
Trial: 35304396
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (three cycles of CapeOx plus bevacizumab) followed by CRT and consolidation chemotherapy (three cycles of CapeOx)
Trial: 36017934
Drug: Local simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local simvastatin (SIM) 2.2 mg in methylcellulose (SIM/MCL)
Trial: 35762321
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (4 grams daily)
Trial: 33288862
Drug: Midostaurin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin (50 mg twice daily) with standard-of-care (SOC)
Trial: 37125529
Drug: sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 200 mg
Trial: 35058583
Drug: sacubitril/valsartan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan (both doses)
Trial: 35234826
Drug: Gentamicin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin treatment
Trial: 34574458
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) products (Angelicae Sinensis Radix, Astragali Radix, Salviae Miltiorrhizae Radix et Rhizoma) administered orally for two weeks
Trial: 34663787
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy
Trial: 34763615
Drug: Brief Relational
RxNorm normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Relational Therapy (BRT)
Trial: 35150156
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 0.9 mg daily for 6 months
Trial: 32188111
Drug: Q10Vital® water-soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q10Vital® water-soluble CoQ10 syrup (investigational product)
Trial: 32188111
Drug: Ubiquinol capsules
RxNorm normalized name: ubiquinol Oral Capsule
DrugBank: Ubiquinol (DB11340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol capsules (comparative product)
Trial: 32188111
Drug: Ubiquinone capsules
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ubiquinone capsules (standard product)
Trial: 32202330
Drug: 3 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/day Zataria multiflora extract (Z3) for 2 months
Trial: 32202330
Drug: 6 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg/day Zataria multiflora extract (Z6) for 2 months
Trial: 32107487
Drug: TIVA (target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (target-controlled infusion of propofol and remifentanil)
Trial: 32107487
Drug: BGA (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGA (continuous remifentanil infusion and sevoflurane inhalation)
Trial: 32522698
Drug: Epinephrine ≥3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine ≥3 mg
Trial: 32522698
Drug: Epinephrine <3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine <3 mg
Trial: 37306651
Drug: Transcatheter edge‐to‐edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter edge‐to‐edge repair (TEER) with MitraClip plus guideline‐directed medical therapy (GDMT)